Latest Publicationsadmin2018-09-22T13:20:48+00:00 Featured Article Intern Med J. 2018 Front-line management of non-Hodgkin lymphoma in Australia. Part 1: follicular lymphoma Trotman J, Cheah CY, Marlton P, Opat S PDF Article More Publications A Multi-Center Retrospective Comparison of Induction Chemoimmunotherapy Regimens on Outcomes in Transplant-eligible Patients with Previously Untreated Mantle Cell Lymphoma.Source: Dr Chan CheahPublished on 2019-04-16PiggyBac transposon tools for recessive screening identify B-cell lymphoma drivers in mice.Source: Dr Carolyn GrovePublished on 2019-03-31Front-line management of indolent non-Hodgkin lymphoma in Australia. Part 2: mantle cell lymphoma and marginal zone lymphoma.Source: Dr Chan CheahPublished on 2019-03-01The effect of tyrosine kinase inhibitor interruption and interferon use on pregnancy outcomes and long-term disease control in chronic myeloid leukemia.Source: Dr David JoskePublished on 2019-01-12Rituximab in patients with primary CNS lymphoma (HOVON 105/ALLG NHL 24): a randomised, open-label, phase 3 intergroup study.Source: Dr Gavin CullPublished on 2019-01-12Stage I non-Hodgkin lymphoma: no plateau in disease-specific survival ?Source: Dr Chan CheahPublished on 2019-01-09‘It is a journey of discovery’: living with myeloma.Source: Dr Bradley AugustsonPublished on 2018-10-29‘It is a journey of discovery’: living with myeloma.Source: Dr David JoskePublished on 2018-10-29Improvement in Parameters of Hematologic and Immunologic Function and Patient Well-being in the Phase III RESONATE Study of Ibrutinib Versus Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.Source: Dr Gavin CullPublished on 2018-09-26Translocation (X;20) involving the inactive X chromosome in a patient with myeloproliferative disorder.Source: Dr Julie CrawfordPublished on 2018-09-21Safety and efficacy of pegfilgrastim compared to granulocyte colony stimulating factor (G-CSF) supporting a dose-intensive, rapidly cycling anti-metabolite containing chemotherapy regimen (Hyper-CVAD) for lymphoid malignancy.Source: Dr Julie CrawfordPublished on 2018-09-21Prolonged haematological toxicity from the hyper-CVAD regimen: manifestations, frequency, and natural history in a cohort of 125 consecutive patients.Source: Dr Julie CrawfordPublished on 2018-09-21Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman’s disease.Source: Dr Julie CrawfordPublished on 2018-09-21Front-line management of non-Hodgkin lymphoma in Australia. Part 1: follicular lymphoma.Source: Dr Chan CheahPublished on 2018-09-20Impact of histologic subtypes and treatment modality among patients with primary central nervous system lymphoma: a SEER database analysis.Source: Dr Chan CheahPublished on 2018-07-11 Older posts
Kobe Creations